1,211
+0.41%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Samsung Pharm Co
Its shares trade on KRX under the ticker 001360.KS. It has been listed since 4 July 1975. In the fiscal year to 31 December 2025, it reported revenue of ₩46.07bn and net income of ₩11.55bn. At that date it held total assets of ₩167.44bn and shareholders' equity of ₩121.04bn.
SAMSUNG PHARMACEUTICAL Co., Ltd. engages in the manufacture and distribution of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do. Co., LTD., formerly SAMSUNG PHARMACEUTICAL.CO.,Ltd., is a Korea-based company principally engaged in the manufacture and sale of pharmaceuticals. The firm operates its business through two segments. The Pharmaceutical and Quasi-drug Sale Business segment manufactures and sells prescription medicines, general pharmaceuticals and quasi-medicines. This segment's products include anticancer immunotherapy agents, antipyretic analgestic and anti-inflammatory agents, hypotensive agents, antiarteriosclerotic agents, anti-spastics, enzyme agents, ostepoposis agents, antibiotics, medicines for digestive system, medicines for liver disorder, medicines for circulation system and vitamin supplements, among others. The Health Food Manufacturing and Sale segment manufactures and sells nutrition and invigoration products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 4 Jul 1975
- Employees
- 89
Leadership
Pay as last reported
- Seong Taek JungCo-Chief Executive Officer, Director, since 2023
- Mr. Sang Jae KimCo-Chief Executive Officer, Director, since 2015
- Cheol Jun ParkDirector
- Chun Ho NohIR Contact Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Samsung Pharm Co Ltd manufactures anticancer immunotherapy agents and antipyretic analgestic agents in Hwaseong, KR.
- The company employs 89 full-time employees in the Health Care sector with a focus on pharmaceuticals.
- Samsung Pharm Co Ltd operates two business segments: Pharmaceutical and Quasi-drug Sale Business.
Weaknesses
- Samsung Pharm Co Ltd has 89 employees, which is a small workforce for a pharmaceutical company.
- The company's business is limited to two segments: Pharmaceutical and Quasi-drug Sale Business.
- Samsung Pharm Co Ltd is headquartered in Hwaseong, Gyeonggi-Do, a small city in South Korea.
Opportunities
- Samsung Pharm Co Ltd can expand its pharmaceutical products to include new anticancer immunotherapy agents.
- The Health Food Manufacturing and Sale segment offers opportunities for growth in nutrition and invigoration products.
- The company can leverage its 89 employees to increase productivity in the Health Care sector.
Threats
- Samsung Pharm Co Ltd faces competition from larger pharmaceutical companies in the Health Care sector.
- The company's small size with 89 employees may limit its ability to compete globally.
- The Health Food Manufacturing and Sale segment is subject to regulatory changes in South Korea.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.